$ 36.66
Updated 01:00:00
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 1,112,813
High $ 37.53
Low $ 35.57
Open $ 36.91
ISIN
Prev close $ 36.99
# of shares 173.09M
Market cap 6,345.30M USD
Intraday

Market closed
Nektar Therapeutics
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  36.66 -3.5% Stock price decreasing 7.8% Stock price increasing -43.1% Stock price decreasing -30.9% Stock price decreasing -33.6% Stock price decreasing
Powered by TradingView

News about Nektar Therapeutics

  • English
  • Regulatory news
10 Dec
 
10 Dec
 
10 Dec
 
10 Dec
 
09 Dec
 
07 Dec
 
07 Dec
 
07 Dec
 
06 Dec
 
06 Dec
 

Company profile

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop NKTR-214, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
11 December 2018 09:57:47
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB5 - 2018-12-11 10:57:47 - 2018-12-11 09:57:47 - 1000 - Website: OKAY